Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy

Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy

Copyright © 2018 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 195(2018) vom: 01. Okt., Seite 18-27
1. Verfasser: Caporuscio, Sara (VerfasserIn)
Weitere Verfasser: Ieraci, Roberto, Valesini, Guido, Teloni, Raffaela, Mariotti, Sabrina, Spinelli, Francesca Romana, Ferlito, Claudia, Salemi, Simonetta, Picchianti Diamanti, Andrea, Meneguzzi, Giorgia, Markovic, Milica, Sgrulletti, Mayla, von Hunolstein, Christina, Ralli, Luisa, Pinto, Antonietta, Salerno, Gerardo, Canzoni, Marco, Sorgi, Maria Laura, Laganà, Bruno, Di Rosa, Roberta, Nisini, Roberto, D'Amelio, Raffaele
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't 13-valent pneumococcal conjugate vaccine Antibody persistence Immunogenicity Immunosuppressive therapy Rheumatoid arthritis 13-valent pneumococcal vaccine Antibodies, Bacterial Immunoglobulin G mehr... Immunosuppressive Agents Pneumococcal Vaccines Polysaccharides, Bacterial
LEADER 01000naa a22002652 4500
001 NLM286769867
003 DE-627
005 20231225052507.0
007 cr uuu---uuuuu
008 231225s2018 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2018.07.010  |2 doi 
028 5 2 |a pubmed24n0955.xml 
035 |a (DE-627)NLM286769867 
035 |a (NLM)30036638 
035 |a (PII)S1521-6616(18)30191-8 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Caporuscio, Sara  |e verfasserin  |4 aut 
245 1 0 |a Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy 
264 1 |c 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 27.08.2019 
500 |a Date Revised 27.08.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2018 Elsevier Inc. All rights reserved. 
520 |a Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a 13-valent pneumococcal conjugate vaccine 
650 4 |a Antibody persistence 
650 4 |a Immunogenicity 
650 4 |a Immunosuppressive therapy 
650 4 |a Rheumatoid arthritis 
650 7 |a 13-valent pneumococcal vaccine  |2 NLM 
650 7 |a Antibodies, Bacterial  |2 NLM 
650 7 |a Immunoglobulin G  |2 NLM 
650 7 |a Immunosuppressive Agents  |2 NLM 
650 7 |a Pneumococcal Vaccines  |2 NLM 
650 7 |a Polysaccharides, Bacterial  |2 NLM 
700 1 |a Ieraci, Roberto  |e verfasserin  |4 aut 
700 1 |a Valesini, Guido  |e verfasserin  |4 aut 
700 1 |a Teloni, Raffaela  |e verfasserin  |4 aut 
700 1 |a Mariotti, Sabrina  |e verfasserin  |4 aut 
700 1 |a Spinelli, Francesca Romana  |e verfasserin  |4 aut 
700 1 |a Ferlito, Claudia  |e verfasserin  |4 aut 
700 1 |a Salemi, Simonetta  |e verfasserin  |4 aut 
700 1 |a Picchianti Diamanti, Andrea  |e verfasserin  |4 aut 
700 1 |a Meneguzzi, Giorgia  |e verfasserin  |4 aut 
700 1 |a Markovic, Milica  |e verfasserin  |4 aut 
700 1 |a Sgrulletti, Mayla  |e verfasserin  |4 aut 
700 1 |a von Hunolstein, Christina  |e verfasserin  |4 aut 
700 1 |a Ralli, Luisa  |e verfasserin  |4 aut 
700 1 |a Pinto, Antonietta  |e verfasserin  |4 aut 
700 1 |a Salerno, Gerardo  |e verfasserin  |4 aut 
700 1 |a Canzoni, Marco  |e verfasserin  |4 aut 
700 1 |a Sorgi, Maria Laura  |e verfasserin  |4 aut 
700 1 |a Laganà, Bruno  |e verfasserin  |4 aut 
700 1 |a Di Rosa, Roberta  |e verfasserin  |4 aut 
700 1 |a Nisini, Roberto  |e verfasserin  |4 aut 
700 1 |a D'Amelio, Raffaele  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 195(2018) vom: 01. Okt., Seite 18-27  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:195  |g year:2018  |g day:01  |g month:10  |g pages:18-27 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2018.07.010  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 195  |j 2018  |b 01  |c 10  |h 18-27